文献速递细胞病理与分子病理神经与头颈病理

Cobas HPV检测在头颈部FNA标本中对高危HPV的检测准确性

Detection accuracy of the Cobas HPV assay for high-risk HPV in head and neck FNA biopsy specimens.
PubMed 文献 · Cancer Cytopathol · 2022-02-22

本研究回顾性收集2012至2020年头颈部细针穿刺(FNA)标本,对90例有Cervista HPV有效结果的标本行Cobas HPV检测并比较,不一致病例用Linear Array或SPF10-LiPA25分型验证。Cobas HPV与Cervista结果一致率88.9%(κ=0.669),经分型确认后Cobas对hrHPV的敏感性和特异性均为100%,对HPV-16准确性97.8%,在42例针头冲洗标本中准确性100%。

要点

  • Cobas HPV与Cervista结果一致率88.9%,一致性强度为显著(κ=0.669)。
  • 经分型确认后Cobas HPV对hrHPV的敏感性和特异性均为100%。
  • Cobas HPV在FNA针头冲洗标本中准确性为100%。

核心结论

  • Cobas HPV检测在头颈部FNA标本中判断HPV状态具有高准确性。
  • FNA针头冲洗标本可用于鳞状细胞癌患者的Cobas HPV检测。

研究设计与样本

  • 回顾性收集2012至2020年头颈部FNA活检标本。
  • 对90例有Cervista HPV有效结果的FNA标本行Cobas HPV检测并比较两种检测结果。
  • 结果不一致的病例用Linear Array或SPF10-LiPA25 HPV分型检测解决。
  • 计算Cobas HPV检测的κ值和准确性。
  • 另在42例FNA针头冲洗标本中评估Cobas HPV检测的准确性。

主要发现

  • Cobas HPV在82%的FNA标本中为阳性(74/90)。
  • Cobas HPV与Cervista HPV结果一致率为88.9%(80/90),一致性强度为显著(κ=0.669;95%CI,0.481-0.856)。
  • 经HPV分型确认不一致病例后,Cobas HPV对hrHPV的敏感性和特异性均为100%。
  • HPV阳性病例中HPV-16占88%(65/74)。
  • HPV分型确认1例HPV-16假阴性和1例HPV-16假阳性,Cobas HPV对HPV-16的总体准确性为97.8%。

临床怎么用

  • 对头颈部鳞状细胞癌FNA标本可用Cobas HPV检测判断hrHPV状态。
  • FNA针头冲洗标本可作为Cobas HPV检测的合法样本类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the detection accuracy of the Cobas human papillomavirus (HPV) assay for high-risk human papillomavirus (hrHPV) and HPV-16 in head and neck fine-needle aspiration (FNA) specimens with squamous cell carcinoma. METHODS: Head and neck FNA biopsy specimens from 2012 to 2020 were retrospectively collected. Cobas HPV testing was performed on 90 FNA specimens with valid Cervista HPV testing results. Results of Cobas HPV and Cervista HPV assays were compared. A Linear Array or SPF10-LiPA25 HPV genotyping assay resolved cases with discrepant results. The κ value and accuracy of Cobas HPV testing were calculated. The accuracy of the Cobas HPV assay was also determined in 42 FNA needle-rinse specimens. RESULTS: Cobas HPV was positive in 82% of the FNA specimens (74 of 90). The concordance between Cobas HPV and Cervista HPV test results was 88.9% (80 of 90) with substantial agreement (κ = 0.669; 95% CI, 0.481-0.856). With HPV genotyping confirmation in cases with discrepant results between the 2 HPV assays, Cobas HPV showed 100% sensitivity and specificity for hrHPV. HPV-16 was detected in 88% of HPV-positive cases (65 of 74). HPV genotyping confirmed 1 false-negative HPV-16 result and 1 false-positive HPV-16 result. Overall, the accuracy of Cobas HPV for HPV-16 was 97.8%. The accuracy of Cobas HPV in FNA needle-rinse specimens was 100%. CONCLUSIONS: The Cobas HPV assay is highly accurate for determining the HPV status in head and neck FNA specimens. FNA needle rinse is valid for Cobas HPV testing in patients with squamous cell carcinoma.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Guo M, Khanna A, Tinnirello AA, et al. Detection accuracy of the Cobas HPV assay for high-risk HPV in head and neck FNA biopsy specimens. Cancer Cytopathol. 2022. PMID: 35192231. doi:10.1002/cncy.22563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。